Pfizer (PFE) Subsidiary Enters Epinephrine Auto-Injector Settlement (MYL) (SNY)
Up)
Mylan Inc. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) report that Meridian Medical Technologies, a Pfizer subsidiary, has entered into a settlement agreement with Intelliject and Sanofi-Aventis (NYSE: SNY) that will resolve pending patent litigation related to Intelliject's 505(b)(2) new drug application (NDA) for its epinephrine auto-injector known as e-cue, which will be manufactured and marketed by Sanofi-Aventis. According to the terms of the settlement, Intelliject and Sanofi-Aventis may launch e-cue no earlier than Nov. 15, 2012, subject to receipt of final approval from the U.S. Food and Drug Administration.
Meridian manufactures EpiPen Auto-Injector and Mylan Specialty markets and distributes the product in the United States.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Meridian manufactures EpiPen Auto-Injector and Mylan Specialty markets and distributes the product in the United States.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Mylan (MYL) Launches Generic Bonviva Tabs (RHHBY) in Italy & the U.K.
- Mylan (MYL) Unit Launches Generic Viramune Tabs
- Euroseas (ESEA) commences 13.9M rights offering
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
